Upcoming FDA Meeting on PTSD, The Ketamine Dilemma, and the Rise of ‘Lifestyle Psychiatry’

The FDA will be holding a meeting next week to discuss advancements in treating post-traumatic stress disorder. A recent study found that female doctors have a higher risk of suicide compared to the general population. The Atlantic examined the complex situation surrounding the use of ketamine. Neurocrine Biosciences reported positive results in a study on an investigational treatment for schizophrenia. ProPublica investigated state mental health laws and issues in Kentucky related to housing patients with mental illness. While an investigational drug for cognitive dysfunction and major depressive disorder did not meet its primary goal, it showed promise in treating depression. Lifestyle psychiatry is becoming more popular, and inflammatory biomarkers have been linked to a higher risk of developing psychiatric disorders. The Surgeon General issued a statement urging more support for parents’ and caregivers’ mental health. More than 500 therapists spoke out about the challenges of going out-of-network. Epic Research data revealed a link between diabetes, Alzheimer’s disease, and HbA1c levels. Rep. Yadira Caraveo shared her own experience with depression to help destigmatize mental illness. Kristen Monaco, a senior staff writer focusing on endocrinology, psychiatry, and nephrology news, will cover these topics from the company’s New York City office.

Source
Photo credit www.medpagetoday.com